These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11751486)

  • 1. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
    Fidias P; Supko JG; Martins R; Boral A; Carey R; Grossbard M; Shapiro G; Ostler P; Lucca J; Johnson BE; Skarin A; Lynch TJ
    Clin Cancer Res; 2001 Dec; 7(12):3942-9. PubMed ID: 11751486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
    Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
    Socinski MA
    Oncologist; 1999; 4(5):408-16. PubMed ID: 10551557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.
    Juan O; Albert A; Villarroya T; Sánchez R; Casan R; Caranana V; Campos JM; Alberola V
    Neoplasma; 2003; 50(3):204-9. PubMed ID: 12937854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.
    Sekine I; Nishiwaki Y; Watanabe K; Yoneda S; Saijo N
    Clin Cancer Res; 1996 Jun; 2(6):941-5. PubMed ID: 9816254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
    Stathopoulos GP; Katis C; Tsavdaridis D; Dimitroulis J; Karaindros D; Stathopoulos J; Dimou E
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):555-60. PubMed ID: 16520987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
    Richards DA; Richards P; Bodkin D; Neubauer MA; Oldham F
    Clin Lung Cancer; 2005 Nov; 7(3):215-20. PubMed ID: 16354318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.